Royalty Pharma plc (RPRX)
NASDAQ • Healthcare
Last close at September 11, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Royalty Pharma plc keeps $3 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 52 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Royalty Pharma plc beat consensus on adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, with adjusted EPS of $1.32 topping the $1.27 estimate by 3.9% and rising 15.8% from $1.14 a year ago. Revenue rose 16.5% to about $674.1 million from $578.7 million a year earlier, while gross profit came in at about $405.9 million and gross margin held near 60%; operating income was about $133.0 million, with operating margin near 20%. The company generated operating cash flow of about $728.0 million and paid $105.0 million in dividends. Consensus for the next period calls for EPS of $1.12.
About Royalty Pharma plc
Royalty Pharma plc (NASDAQ: RPRX) operates in healthcare as a buyer of biopharmaceutical royalties and a funder of drug innovation, centered on the United States. The company records revenue from royalty interests tied to approved and pipeline medicines, and generated $2.4 billion in FY2025.
Today's Snapshot
RPRX closed slightly lower at 58.61, in line with a flat sector.
Trading Volume
Below 10d avg (3.6M)
2.5M
vs S&P 500 Today
Underperforming Market
-1.17%
Updated: September 11, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$50.18 - $60.75Sell
- RSI (14)41.71Neutral
- Stochastic %K (14, 3, 3)13.50Buy
- MACD Level (12, 26)0.41Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.